CA3243643A1 - WEIGHT LOSS METHODS FOR A SUBJECT WITH HIGH HbA1C - Google Patents
WEIGHT LOSS METHODS FOR A SUBJECT WITH HIGH HbA1CInfo
- Publication number
- CA3243643A1 CA3243643A1 CA3243643A CA3243643A CA3243643A1 CA 3243643 A1 CA3243643 A1 CA 3243643A1 CA 3243643 A CA3243643 A CA 3243643A CA 3243643 A CA3243643 A CA 3243643A CA 3243643 A1 CA3243643 A1 CA 3243643A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- reduction
- effective amount
- therapeutically effective
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263307470P | 2022-02-07 | 2022-02-07 | |
| US63/307,470 | 2022-02-07 | ||
| US202263382426P | 2022-11-04 | 2022-11-04 | |
| US63/382,426 | 2022-11-04 | ||
| PCT/US2023/062065 WO2023150759A1 (en) | 2022-02-07 | 2023-02-06 | Methods of weight loss in a subject with elevated hba1c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3243643A1 true CA3243643A1 (en) | 2023-08-10 |
Family
ID=85569618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3243643A Pending CA3243643A1 (en) | 2022-02-07 | 2023-02-06 | WEIGHT LOSS METHODS FOR A SUBJECT WITH HIGH HbA1C |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250134865A1 (https=) |
| EP (1) | EP4475842A1 (https=) |
| JP (1) | JP2025505632A (https=) |
| KR (1) | KR20240146053A (https=) |
| AU (1) | AU2023214495A1 (https=) |
| CA (1) | CA3243643A1 (https=) |
| IL (1) | IL314682A (https=) |
| MX (1) | MX2024009644A (https=) |
| WO (1) | WO2023150759A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3565806T (pt) | 2017-01-06 | 2022-05-19 | Rivus Pharmaceuticals Inc | Novos derivados de fenilo |
| WO2022246039A1 (en) * | 2021-05-20 | 2022-11-24 | Rivus Pharmaceuticals, Inc. | Methods of treating mitochondria-related disorders |
-
2023
- 2023-02-06 WO PCT/US2023/062065 patent/WO2023150759A1/en not_active Ceased
- 2023-02-06 US US18/835,578 patent/US20250134865A1/en active Pending
- 2023-02-06 IL IL314682A patent/IL314682A/en unknown
- 2023-02-06 JP JP2024546294A patent/JP2025505632A/ja active Pending
- 2023-02-06 CA CA3243643A patent/CA3243643A1/en active Pending
- 2023-02-06 KR KR1020247029814A patent/KR20240146053A/ko active Pending
- 2023-02-06 MX MX2024009644A patent/MX2024009644A/es unknown
- 2023-02-06 EP EP23710591.1A patent/EP4475842A1/en active Pending
- 2023-02-06 AU AU2023214495A patent/AU2023214495A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024009644A (es) | 2024-08-14 |
| EP4475842A1 (en) | 2024-12-18 |
| WO2023150759A1 (en) | 2023-08-10 |
| IL314682A (en) | 2024-10-01 |
| AU2023214495A1 (en) | 2024-08-15 |
| US20250134865A1 (en) | 2025-05-01 |
| JP2025505632A (ja) | 2025-02-28 |
| KR20240146053A (ko) | 2024-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220152053A1 (en) | Methods and compositions for treating various disorders | |
| CN107683135A (zh) | 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法 | |
| JP2017513836A (ja) | Ｎａｆｌｄおよびｎａｓｈの治療 | |
| JP2012520866A (ja) | 高用量のウルソデオキシコール酸で非アルコール性脂肪性肝炎を治療する方法 | |
| CN117677395A (zh) | 长效glp1/胰高血糖素受体激动剂的剂量方案 | |
| TW202114671A (zh) | 包含fxr促效劑之治療 | |
| US20250134864A1 (en) | Methods of weight loss and preserving skeletal muscle mass | |
| TW202313010A (zh) | 治療粒線體相關病症之方法 | |
| TW202114654A (zh) | 包含如sglt 1/2抑制劑的sglt抑制劑之治療 | |
| US20250134865A1 (en) | Methods of weight loss in a subject with elevated hba1c | |
| CN111386115A (zh) | 用于治疗非酒精性脂肪性肝炎的方法和药物组合物 | |
| CN118900692A (zh) | HbA1c升高的受试者的体重减轻方法 | |
| CN118922187A (zh) | 体重减轻和保持骨骼肌量的方法 | |
| CN117881399A (zh) | 治疗粒线体相关病症的方法 | |
| WO2026046202A1 (zh) | Glp-1/gip肽或含有其的药物组合物的用途 | |
| TW202500575A (zh) | 具有或不具有體重相關合併症之過重或肥胖成人之治療 | |
| CN110038014A (zh) | 血红素在改善夜间尿频的药物、食品及保健食品中的应用 | |
| EP4346830A1 (en) | Use of complement factor d inhibitor for treatment of geographic atrophy secondary to age-related macular degeneration | |
| WO2026037397A1 (zh) | Glp-1类似物的医药用途 | |
| JP2018108969A (ja) | リンパ浮腫の治療薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240801 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240802 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240802 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240802 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241003 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241220 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241220 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241220 |